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ABSTRACT 
 
 
A transgenic animal carries foreign DNA deliberately inserted into its genome for 
specific scientific purposes.  Transgenic animals can be engineered to improve human welfare in 
agriculture, industry, and medicine.  Although the use of these animals in research provides 
benefits and new hope for discovery in many scientific fields, there still exist questions and 
ethical concerns regarding the usage and creation of such animals.  The purpose of this project is 
to provide a brief understanding of what DNA is and how it works within a cell, along with 
dwelling on the specific methods scientists use to create transgenic animals.  This project also 
aims to highlight the most notable transgenic animals created to date, and also to examine the 
legal and ethical ramifications of this technology.  It is concluded that despite public criticism, 
transgenic animals are an important technology of the future and offer society very strong 
benefits. 
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PROJECT OBJECTIVES 
 
The objective of this project is to explore the quickly developing technology of 
transgenic animals while gaining an understanding of the benefits, ethics, and legal issues 
associated with these animals.  The report will define transgenic animals, explain the most 
popular methods used to create them, highlight each major category using examples, discuss 
ethical concerns, and examine current laws that regulate transgenesis and animal patenting.  In 
both scientific and lay communities, transgenesis is considered one of the more controversial 
bio-technologies. Therefore this report aims to accurately provide sufficient information to the 
reader to help them decide whether to support transgenic research.  
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CHAPTER-1: TRANSGENIC ANIMAL TECHNOLOGY 
Paul Cupido 
 
 A transgenic animal is an animal that carries foreign DNA deliberately inserted into its 
genome.  The inserted gene is incorporated into the DNA of the host and is eventually expressed 
by its cells, creating an organism with new properties that normally would not exist in nature.  
Transgenic animals are a valuable tool for exploring many biological questions, for better 
understanding diseases, and for producing new drugs for saving human lives.  Without the use of 
animals as models for human disease, the likelihood of medical breakthrough is significantly 
reduced.  Transgenic animals allow for more efficient scientific advancement due to the 
inexpensive cost of housing lab animals, their short life cycles, and their rapid reproduction rates.   
Although such animals benefit society, what is the cost to the animals?  To gain a better 
understanding of this technology, it is important to first become familiar with the process of 
transgenesis, the most common ways of creating transgenic animals, and how to screen for the 
transgenic positives. 
 The two most common ways transgenic animals are created are by pronuclear 
microinjection and embryonic stem cell manipulation, each providing its own advantages.  But 
before understanding how scientists use these processes to create a transgenic animal, we must 
first understand the foundation of biology, DNA. 
 
DNA:  The Molecular Basis of Life 
 DNA is not only considered the molecular basis of life, but also the molecule that ties all 
life together.  DNA, once transcribed to mRNA, is then translated to proteins which perform all 
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the functions necessary for life.  DNA, regardless of its source from bacteria to human beings, is 
composed of the same basic subunits, making transgenics possible.  These subunits, also known 
as nucleotides, are paired like the rungs of a ladder against a sugar and phosphate backbone 
(Figure-1).  Weak hydrogen bonds hold each nucleotide base pair together in a double helix 
structure.    
 
 
 
 
Figure-1: DNA Structure.  Shown on the 
left is the unique shape of DNA, with its 
double helical structure.  On the right is 
shown the specific base pairs held together by 
hydrogen bonds .  (Goodenough and 
McGuire, 2010). 
 
 
 
 
 
The four nitrogenous bases which make up the core code of DNA are adenine (A), 
guanine (G), thymine (T), and cytosine (C).   These bases follow the rules of complementary 
base pairing discovered by two scientists, James Watson and Francis Crick circa 1953 (Crick and 
Watson, 1953; Kimball, 2011).  These rules, based on structural constraints, state that only 
adenine can pair with thymine, and guanine can only pair with cytosine (Figure-2).  This 
bonding of base pairs is so specific, that the bases on one strand of DNA are always 
complementary to the bases on the other strand (Goodenough and McGuire, 2010).  Since each 
DNA strand is complementary, DNA can be replicated using each parental strand as a template 
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for a complementary daughter strand, then its message can be read by other functioning 
molecules in the cell.   
 
 
 
 
 
 
 
 
So how are phenotypic traits related to an organism’s DNA?   The exact order of a DNA 
strand’s nucleotide code determines the amino acid sequence for making a protein.  Gregor 
Mendel (Figure-3), an Austrian monk/scientist who published a paper in the Proceedings of the 
Natural History Society of Brünn in 1866, was the first to help prove that physical characteristics 
of an organism were determined by genotype.  In an experiment with pea plants, he bred two 
different strains and formulated three laws of inheritance: 
(1) each trait inherited by an offspring is determined by a 
specific element, today called genes, (2) each trait or gene 
is inherited separately, and (3) each inherited trait is 
determined by the intersection of two genes, one from each 
parent, with one trait always dominant over the other 
(Gregor Mendel, 2002).  These three ideas opened the 
flood gates for further research and discoveries in genetics.   
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In 1928, Frederick Griffith used Mendel’s work to discover the phenomenon of 
transformation. He was able to convey specific traits from dead bacteria by mixing them with 
living bacteria that took up the “trait molecule” and expressed it.  Sixteen years later, in 1944, 
Oswald Avery, Colin MacLeod, and Maclyn McCarty identified DNA as the molecule capable 
of this transformation, rather than protein which was strongly suspected by scientists at the time 
based on its greater complexity.  In 1952, DNA was confirmed as the molecule controlling 
heredity by Alfred Hershey and Martha Chase (Figure-4) who used a system composed of a 
DNA virus infecting a bacterium to show that the infecting material was DNA and not protein.  
Using this previous evidence as the foundation for their work, Watson and Crick discovered the 
structure of DNA to be further supporting evidence of Mendel’s theories.  Powered by the 
knowledge and understanding of the structure of DNA, and how the genetic code worked, 
scientists figured out ways to isolate, manipulate, and clone DNA thus opening up a 
revolutionary door to the world of transgenics. 
 
 
Figure-4: The Hershey-Chase Experiment. 
Using bacteriophages composed of both protein and 
DNA, in 1952 it was proved that DNA enters and 
infects the host cell as the genetic material.  Sulfur 
was used as an indicator for protein, and phosphorous 
as an indicator for DNA, and the phosphorus entered 
the host cell.  (The Hershey-Chase Blender 
Experiment, 2009).     
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Creating the Transgene 
Transgene Structure 
 The first step in creating a transgenic animal is to isolate and create the foreign gene that 
will be inserted into the animal.  A transgene is an artificial gene, and transgene structure must 
contain all the critical elements for gene expression (Figure-5).  A transgene contains a 
promoter, an intron, a protein coding sequence, and a stop sequence (Wallace et al., 2011).  
These critical structure elements exist in 3-adjacent nucleotide long sequences known as codons.  
The promoter is a segment of DNA which facilitates transcription of a particular gene.  It creates 
a secure initial binding site for RNA polymerase, allowing for transcription into mRNA.  The 
promoter sequence is also responsible for determining in which cells and at what time the 
transgene is active (Wallace et al., 2011).  Introns are the non-protein coding region of the 
transgene, linked to gene-regulation function.  They can be spliced out in alternative ways during 
DNA reproduction, allowing for a single gene to encode several varying versions of the same 
protein under different circumstances.   
 
 
Figure-5: Transgene Structure.  Basic structure of a transgene contains a promoter upstream, 
cDNA of the gene of interest, intron sequences and a stop codon.  The untranslated region (UTR) 
must be included for proper gene regulation. Intron sequences do not necessarily need be from the 
gene of interest (Charles River, 2005). 
 
 
The protein coding sequence, also known as an exon, is the main part of the transgene a 
researcher is focused on.  Exons code for a specific portion of a protein and are joined together 
when the introns dividing them are removed in the RNA.  These multiple exons, when edited to 
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make mature RNA, are translated to form complete proteins.  The stop sequence following the 
coding sequence signals termination within the messenger RNA to halt protein translation. 
 
Isolating and Manipulating DNA 
 To create a transgene, scientists must be able to isolate a particular gene of interest and 
then have the ability to add, delete, or rearrange a section of it for study.  Creating these DNA 
sequences not normally found in biological organisms is called making recombinant DNA 
(rDNA).  Once rDNA is prepared, it is inserted into a vector (plasmid or virus) and is ready for 
insertion into a cell.  The process for manipulating DNA is a “cut and paste” method requiring 
the use of restriction enzymes and DNA ligase (Figure-6).  A restriction enzyme binds to a DNA 
molecule at a recognition site in the DNA and cleaves it.  Restriction enzymes are exclusively 
chosen to generate DNA fragments with “sticky ends” that are capable of being linked to other 
compatible DNA segment ends.  
 
 
Figure-6:  Cutting DNA With EcoRI 
Restriction Enzyme.  Shown is an example of 
a restriction enzyme, EcoRI.  The enzyme has a 
precise shape that allows it to run along the grove 
of the DNA double helix, scanning for the base 
letter sequence GAATTC.  When it recognizes 
that sequence, it cuts the strands between the G 
and A, leaving sticky ends for recombinant DNA 
to be formed (Thompson, 2010).  
 
 
 
Typically the cloning vector is treated with the same restriction enzyme as the 
recombinant DNA to ensure compatibility.  Once the vector is ready to receive the foreign 
rDNA, the two are mixed together, and sealed with DNA ligase.  The resulting mixture contains 
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vector DNA linked to the foreign DNA.  The mixture is sorted out in the cloning process once 
the DNA mixture is introduced into the host cells.   
 
Gene Cloning 
 Experiments involving transgenic animals require a relatively large amount of rDNA, so 
the DNA is usually cloned and amplified prior to use.  Viruses/plasmids used for transgenesis are 
normally mutated to create specific properties suitable for cloning (Cohen et al., 1973).  For 
example, a plasmid can contain an ampicillin-resistant gene (amp
r
) used to select for positive 
cells containing the plasmid.  The host cells are treated with chemicals (such as calcium-
chloride) to make them permeable to the DNA molecules.  Only a few of these cells take up a 
recombinant plasmid, which is why a marker gene such as amp
r
 is so useful.  The cells are 
poured onto a nutrient agar plate containing an antibiotic, in this case ampicillin.  The host cells 
which have not accepted the plasmid, lack the ampicillin-resistant gene and die.  Cells that have 
transformed with the plasmid are resistant to ampicillin and should produce successful colonies.  
As the host cell’s chromosome replicates, the plasmid also replicates and segregates to each 
daughter cell, forming a clone.  This method of DNA cloning can be applied to the DNA from 
virtually any organism including bacteria, yeast, plant and animal cells. 
 
Methods of Transgenesis 
 Once a specific rDNA sequence has been created, it must be inserted into an animal and 
expressed by its offspring.  This is called the process of transgenesis.  Various methods have 
been discovered to create transgenic animals, but the most common methods are DNA 
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microinjection into pronuclei, and embryonic stem cell-mediated gene transfer (Margawati, 
2003), each has its own advantages and disadvantages.  
 
Pronuclear Microinjection 
The pronuclear microinjection technique is most commonly used for creating transgenic 
mice.  The first successful genetically modified animal with inserted genes in its offspring was 
created in 1981 using the microinjection method (Gordon and Ruddle, 1981).  Today, mice are 
the most important models for mammalian genetics, much of the technology developed in mice 
is potentially applicable to humans (Griffiths, 2008).  The principles of pronuclear microinjection 
in mice have been applied to other species such as rats, rabbits, birds, fish, sheep and pigs. 
Pronuclear injection involves injecting the foreign DNA directly into the male pronucleus 
of a fertilized egg.  The process begins by collecting female eggs for fertilization.  To produce 
the eggs in mice for example, the female donors are given two hormone injections spaced 46-48 
hours apart (DNA Microinjection Services, 2011).  The hormonal injections induce the female to 
super-ovulate, releasing more than the usual amount of eggs while becoming more receptive to 
mating.  Successful super-ovulation protocols consider the species, age, and weight of the 
animals (Charles River, 2005).  Corresponding fertile male animals are then used to mate with 
the superovulating females.  Breeding should be monogamous, as the presence of other animals 
creates additional technical challenges (Charles River, 2005).  The fertilized eggs are then 
collected before mitosis begins.  It is important that the microinjection occurs before the genetic 
material in an egg replicates, preceding the first cleavage phase in cellular reproduction.  The 
fertilized eggs have a pronucleus from the male and female gametes, which become 
microscopically visible for several hours following the entry of the sperm into the developing 
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egg (Charles River, 2005).  The eggs are examined and visualized using Differential Interference 
Contrast (DIC) optics (Figure-7) in order to locate the injection locus (DNA Microinjection 
Services, 2011).  Using a fine glass micropipette, the cell membrane is delicately penetrated with 
caution to avoid cell damage.  Numerous copies of the desired DNA are injected into either the 
male or female pro-nucleus with approximately 2 to 3 pico-liters of volume.  The male pro-
nucleus is usually best for microinjection because it is larger, more visible, and closer to the egg 
cell’s surface.  
 
 
Figure-7:  DNA Microinjection into the Male 
Pronucleus.  A female egg (center) is held in place 
by a suction pipette (left) while a fine glass pipette 
carrying the foreign DNA (right) prepares to inject 
the DNA solution.  As seen using DIC optics 
(Mullin, 2010). 
 
 
 
If the injection is successful, the DNA can integrate into the chromosomes of the 
pronucleus.  Once the DNA in each pronucleus has duplicated, the male and female pronuclear 
envelopes break down, and the chromosomes align on the metaphase plate to prepare for cell 
division to make the fertilized zygote.  The fertilized zygote divides to form a two-cell stage 
embryo ready for re-implantation into a pseudopregnant surrogate (DNA Microinjection 
Services, 2011).  In order to create a pseudopregnant host capable of receiving the embryos, 
vasectomized male mice are mated with the fertile females.  The process of mating stimulates the 
female reproductive tract to support the development of eggs following surgical implantation.  
Since the males are sterile, the host animal does not become pregnant by that male.  The 
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resulting offspring, known as the founder generation Fo, sometimes possess the transgene.  An F1 
generation of offspring is usually produced by mating specific founder animals together with the 
goal of creating a homozygous genotype. 
  The disadvantage of the pronuclear microinjection technique is that the desired gene 
integrates within the host DNA randomly.  The integration site is a critical determinant of the 
transgene’s expression, so its function may be impaired even though the transgene is present 
(Harper, 1999).  Similarly, the integration of a transgene can occur between functional segments 
in the host DNA, disrupting it.  This can cause an insertional mutation which can negatively 
affect the host animal.   Also, difficulties occur if the transgene is not integrated fast enough into 
the host DNA, or too many copies of it insert into the genome.   The animal will only have some 
of its cells contain the new genetic code, creating an animal known as a “mosaic animal”.  The 
advantages of this method lie in its reliability and widespread use.  Pronuclear injection can be 
used in an abundance of animal species and is often the quickest method.  
 
Embryonic Stem Cell Manipulation 
 Another popular method for creating transgenic animals involves the insertion of the 
desired gene into a culture of embryonic stem (ES) cells.  ES cells are undifferentiated cells that 
have the potential to differentiate into any type of cell in the animal, giving rise to a complete 
organism (Buy, 1997).  ES cells are taken from an in vitro fertilized egg which has been allowed 
to grow for approximately 5-7 days into a blastocyst.  ES cells are located in the inner cell mass 
of an animal blastocyst (Figure-8), and are extracted for culture. 
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Figure-8:  Isolation of Pluripotent Stem Cells. 
Pluripotent stem cells used for ES cell manipulation are 
collected from the inner cell mass of the blastocyst stage 
(upper right), and have the ability to develop into any cell 
in the body (Kochar, 2004).  
 
 
 
 
The ES cell culture is treated with the prepared rDNA containing the gene of interest.  
The vector can be introduced into the ES cell nucleus in a variety of ways including retroviral 
infection, electroporation (the use of electric current to enhance cell permeability), and 
microinjection.  It is important to maintain the stem cells ability to develop into more than one 
type of cell, so the stem cells are co-cultured with feeder layers of embryonic fibroblasts and 
growth factors to help maintain their de-differentiated state (Mudgett and Livelli, 1995).   
 In terms of retroviral insertion of a gene, this type of virus is sometimes used as a vector 
to infect the ES cell lines.  A retrovirus can be “gutted” out to remove all the disease causing 
genes, and that DNA is replaced with the transgene of interest.  The virus, when cultured with 
the ES cells, infects them, releasing its DNA inside the cell for integrating in the host DNA. 
Transgenesis by means of electroporation passes an electric charge through a sample of layered 
DNA and ES cells.  Since DNA is negatively charged, it becomes attracted to positive electrodes 
and passes through the cells made permeable by the electric current.  Microinjection in ES cells 
is similar to the pronuclear method, but is not as widely used.  
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 The advantage of ES cell manipulation is that unlike pronuclear microinjection, 
integration of the DNA into the cell is not random.  The process relies on homologous 
recombination (Figure-9) which is an exchange process that occurs during DNA replication if 
the vector DNA has significant regions of host DNA.  The exchange allows the transgene to be 
inserted at a specific location in the host DNA sequence, lessening the change of transgene 
silencing by integrating in an inactive area.  A transgene is constructed to be flanked by 
sequences homologous to the targeted integration site (Charles River, 2005).  After insertion into 
the nucleus, DNA replication begins and the homologous regions are exchanged.   
 
 
 
 
Figure-9: Homologous Recombination. The targeted gene of interest (exons 1 and 2) is flanked 
by analogous host DNA to promote homologous recombination.  The dotted lines represent the 
“cross-over” point of insertion of the vector DNA into the analogous regions of the host cell 
genome.  Some exons can be replaced with a selectable marker, such as neo
r
 (black) to help select 
for the transgene (Charles River, 2005).  
 
 
The treated ES cells are then screened using methods discussed below to determine 
whether transgenesis was successful.  If the transgene successfully inserted, the modified ES 
cells are re-injected into a blastocyst, and the embryo is inserted into a pseudopregnant surrogate 
mother.  The adult offspring are initially mated with normal males, but the resulting progeny are 
chimeric, having some tissue derived from the original blastocyst cell lines, and some from the 
transplanted ES cell lines (Griffiths, 2008).  From here, the offspring are mated with their 
siblings to eventually produce homozygous animals for the transgene. 
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 Unlike pronuclear microinjection, only one copy of the transgene is inserted into the host 
genome using homologous recombination, helping to dissolve problems with over-expression.  
Unfortunately, this method of creating transgenic animals is very time consuming.  Although the 
site of integration can be highly controlled, the DNA target sequence must be known.  ES cell 
manipulation costs are a lot higher, but testing for the presence of the desired transgene in the 
treated cell line does not require live transgenic offspring (Margawati, 2003).   
Figure-10 compares the two main methods for creating a transgenic animal.  The 
pronuclear method is more reliable, and produces animals with all cells in the body containing 
the transgene, but you cannot control the integration site.  ES cell manipulation allows the 
targeted use of homologous recombination, and screening for transgenic positives at the cell line 
stage prior to implantation.  ES cells can allow for a researcher to use the strategy of gene 
targeting for study; when a normal host gene is substituted for an inactive gene, the targeted 
inactivation is called a gene knockout (Griffiths, 2008).  Pronuclear micro injection is more likely 
to be used to study the “gain-of-function” of multiple copies of a transgene.  Examining the 
phenotype of knock-out or knock-in animals can allow researchers to deduce the function of a 
gene in a biological process (Mullin, 2010).   In addition, it can create models for testing new 
drugs and designing new therapies. 
 
 
Figure-10: Comparison of the Two 
Main Transgenic Methods. Method (1) 
represents ES cell manipulation while 
Method (2) displays pronuclear 
microinjection (Kimball, 2011). 
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Transgenic Animal Screening 
 Since transgenesis is not an efficient process, it is important to screen each transgenic 
animal to determine whether the foreign DNA integrated into its genome. Screening is most 
often performed using Southern Blot assays, RT-PCR, Westerns, or ELISAs.  As one of the more 
reliable methods, a Southern Blot assay (Figure-11) can detect the presence of specific DNA 
sequences in a mixture of DNAs.  Restriction endonucleases are used to cleave the host DNA 
into small fragments.  Then the DNA fragments are electrophoresed on a gel to separate the 
fragments by size (Panel-2 in the figure).  Next, the DNA pattern of fragments is blotted from the 
gel to a membrane (Panel-3 in the figure).  The DNA is fixed onto the membrane, and then 
hybridized to a single stranded DNA probe containing the transgene (Panel-5).  The probe 
contains a marker, usually radioactive or fluorescent, so it can be identified once it binds to the 
target sequence (Panel-6).   
 
  
 
 
Figure-11: Southern Blot Assay Process. 
Simplified steps used for identifying the number of 
copies and presence of a transgene in an animal 
(Southern Blot, 2007). 
 
 
 
 
A Western Blot assay is a similar screening method, but instead of analyzing for the 
presence of a transgene DNA sequence, this assay examines whether the transgenic protein is 
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produced in the host cell.  Cellular proteins are isolated from the host tissue being screened, 
separated by electrophoresis, and blotted to membrane.  Then the membrane is treated with an 
antibody against the transgenic protein.  If the transgenic protein is present on the membrane, the 
antibody binds to it, allowing detection.  A secondary antibody, linked with a marker enzyme, is 
exposed to the samples that binds the primary antibody to enhance the detection signal.  
 Another approach to detecting transgenic proteins is an Enzyme-Linked Immuno-sorbent 
Assay (ELISA).  This technique uses antibodies against the transgenic protein bound to wells in 
a plastic micro-titer dish (Figure-12).  If the transgenic protein is present in the animal’s blood 
or urine, the antibodies in the well capture the protein, anchoring it to the well.  Non-related 
proteins are then washed from the well, and a detection antibody (green in the figure) is used to 
locate and quantitate the transgenic protein in the well.  The detection antibody or its secondary 
antibody, is conjugated to an enzyme that facilitates color formation from a substrate.  
 
 
 
Figure-12: ELISA  Assay.  An example of an 
ELISA plate with the darker colored wells 
providing evidence that more of the targeted 
transgenic protein is present (ELISA, 1998). 
 
  
 
Chapter-1 References 
Biotechnology Information Series: Pharmaceutical Production from Transgenic Animals (2003)  
<http://www.biotech.iastate.edu/biotech_info_series/bio10.html> 
 
Buy, Mary (1997) "Transgenic Animals." Canadian Council on Animal Care. University of 
Calgary, Spring 1997. Web. 7 Aug. 2011. 
<http://people.ucalgary.ca/~browder/transgenic.html>. 
 
20 
 
Charles River (2005) Transgenic Animal Science: Principles and Methods. Wilmington: Charles 
River, 2005. Criver. Charles River Laboratories, Spring 2005. Web. 5 Aug. 2011. 
<http://www.criver.com/SiteCollectionDocuments/rm_tg_r_techbul_sring_05.pdf>. 
 
Cohen SN, Chang AC, Boyer HW, Helling RB (1973) Construction of biologically functional 
bacterial plasmids in vitro. Proc Natl Acad Sci U S A. 70(11): 3240-3244. 
 
Crick FHC, and Watson JD (1953) Molecular Structure of Nucleic Acid.  Nature, 141: 737-738. 
 
"DNA Microinjection Services" (2011) Transgenic Mouse Facility. University of California 
Irvine, 2011. Web. 7 Aug. 2011. <http://research.uci.edu/tmf/dnaMicro.htm#breed>. 
 
Edelson E (1999) "Mendel Is Discovered." Gregor Mendel, and the Roots of Genetics. New 
York: Oxford UP, 1999. 16-17. Google Scholar. Web. 15 July 2011. 
<http://books.google.com/books?id=tvG5B6rmHVQC&dq>. 
 
"ELISA Activity" (1998) The Biology Project. University of Arizona, 21 Jan. 1998. Web. 10 
Aug. 2011. 
<http://www.biology.arizona.edu/immunology/activities/elisa/elisa_intro.html>. 
 
Gibbs WW (2003) "The Unseen Genome: Gems among the Junk." Scientific American. Nature 
America, Inc., 13 Oct. 2003. Web. 23 July 2011. 
<http://www.scientificamerican.com/article.cfm?id=the-unseen-genome-gems-am>. 
 
Goodenough, Judith, and Betty McGuire (2010) "Replication of DNA." Biology of Humans: 
Concepts, Applications, and Issues. 3rd ed. San Francisco: Benjamin Cummings, 2010. 
449-51. Print. 
 
Gordon JW and Ruddle FH (1981) Integration and stable germ line transformation of genes 
injected into mouse pronuclei. Science, 214: 1244-1246 
 
Gossler A, et al. (1986) Transgenesis by means of blastocyst-derived embryonic stem cell line. 
Proc. Natl. Acad. Sci. 83:9065-9069. 
 
Gregor Mendel: From the Garden to the Genome.  Dir. J. Lee Sedwick. By Larry Gardner. 
Digifonics, 2002. 
 
Griffiths A (2008) "Genetic Engineering." Introduction to Genetic Analysis. 9th ed. New York: 
W.H. Freeman and, 2008. 741-55. Print. 
 
Harper SB (1999) "How Transgenics Are Produced." U S Food and Drug Administration. U.S. 
Department of Health & Human Services, July-Aug. 1999. Web. 7 Aug. 2011. 
<http://www.fda.gov/animalveterinary/newsevents/fdaveterinariannewsletter/ucm090231
.htm>. 
 
 
21 
Kimball, John W (2011) "Base Pairing." Kimball's Biology Pages. 2011. Web. 15 July 2011. 
<http://users.rcn.com/jkimball.ma.ultranet/BiologyPages/B/BasePairing.html>. 
 
Kimball, John W (2011) "Transgenic Animals." Kimball's Biology Pages. 13 June 2011. Web. 
27 July 2011. 
<http://users.rcn.com/jkimball.ma.ultranet/BiologyPages/T/TransgenicAnimals.html>. 
 
Kochar PG (2004) "What Are Stem Cells?" ProQuest. Cambridge Information Group, Dec. 
2004. Web. 7 Aug. 2011. <http://www.csa.com/discoveryguides/stemcell/overview.php>. 
 
Margawati, Endang Tri (2003) "Transgenic Animals: Their Benefits To Human Welfare." 
ActionBioscience. American Institute of Biological Sciences, Jan. 2003. Web. 7 Aug. 
2011. <http://www.actionbioscience.org/biotech/margawati.html>. 
 
Mudgett, John S., and Thomas J. Livelli (1995) "Chapter 14: Electroporation of Embryonic Stem 
Cells for Generating Transgenic Mice and Studying In Vitro Differentiation." Ed. Jac A. 
Nickoloff. Animal Cell Electroporation and Electrofusion Protocols. Vol. 48. Totowa, 
NJ: Humana, 1995. 167-84. Print. 
 
Mullin A (2010) "Pronuclear Injection." The Tulane Transgenic Mouse Facility. Tulane 
University, Sept. 2010. Web. 7 Aug. 2011. 
<http://tulane.edu/sse/tgmouse/pronuclear.cfm>. 
 
Rinehart, Claire (2005) "Cloning Vectors for Eukaryotes." WKU Biology Department. Western 
Kentucky University, 2005. Web. 27 July 2011. 
<http://bioweb.wku.edu/courses/biol350/CloningVectEuk9/Review.html>. 
 
"Southern Blot" (2007) Molecular Biology Protocols. Molecular Station, 2007. Web. 11 Aug. 
2011. <http://www.molecularstation.com/dna/southern-blot/>. 
 
"The Hershey-Chase Blender Experiment" (2009) Access Excellence. National Health Museum, 
2009. Web. 17 July 2011. <http://www.accessexcellence.org/RC/VL/GG/hershey.php>. 
 
Thompson, John (2010) "Restriction Enzymes." Environmental Microbiology. Virginia 
Polytechnic Institute and State University.  Web. 5 Aug. 2011. 
<http://filebox.vt.edu/users/chagedor/biol_4684/Methods/restriction.html>. 
 
"DNA Microinjection Services" (2011) Transgenic Mouse Facility. University of California 
Irvine, 2011. Web. 7 Aug. 2011. <http://research.uci.edu/tmf/dnaMicro.htm#breed>. 
 
Wallace, Mia, et al. (2011) "Transgene Design." Mouse Genetics Core. 2011. Washington 
University in St. Louis. Web. 17 July 2011. 
<http://mgc.wustl.edu/Protocols/TransgeneDesign/tabid/153/Default.aspx>. 
 
 
22 
Walsh, Bruce (2003) "Lecture 24: Gene Structure and Evolution." EEB 600A Lecture 24. 
University of Arizona, 15 Apr. 2003. Web. 17 July 2011. 
<http://statistics.arizona.edu/courses/EEB600A-2003/lectures/lecture24/lecture24.html>. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
23 
Chapter-2: Transgenic Applications 
 
Phil O’Sullivan 
 
 
The objective to genetically modify or enhance certain animals indicates that each 
transgenic animal is intended for a purpose. Although hundreds of transgenic animals have been 
created to date, they can be divided into five main categories based on their purpose.  By 
analyzing each category, this chapter will discuss, in depth, the various transgenic animals that 
have been created to date and their purpose, to introduce their benefits to society.  This benefits 
information is important when discussing transgenic ethics in a later chapter.  Transgenic 
animals can be divided into five main categories:  disease models, transpharmers, xeno-
transplanters, food sources, and scientific models.  
 
 
DISEASE MODELS 
 
Transgenic disease models are animals that have been created to provide information on 
how human diseases initiate and progress, and are also used as test subjects for the development 
of possible cures before human testing. These animals are paramount to disease research because 
drugs cannot be FDA approved without animal testing on their safety and efficacy, yet many 
animals do not acquire human-specific diseases. Thus, genetically modifying animals to serve as 
a model for a particular disease allows them to exhibit some of the symptoms and the 
progression of that specific disease so that it may be observed and understood, to facilitate 
research and development of cures. 
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AIDS Mouse 
 
The human immunodeficiency virus (HIV) is a lentivirus that causes acquired 
immunodeficiency syndrome (AIDS).  AIDS is a mostly human-specific condition that causes 
progressive failure of the immune system. Some species of monkeys are infectable with simian 
immunodeficiency virus (SIV), but SIV is not HIV.  And some chimpanzees have been shown to 
be capable of supporting HIV replication (Bunce and Hunt, 2004), but they are expensive.  Thus, 
less expensive animal models for HIV infection would be useful for HIV research.  The creation 
of an AIDS mouse would replace the need to use large, rare, and expensive animals as test 
models, effectively reducing the cost for research exponentially.  
In 2001, the AIDS rat was created at the University of Maryland by microinjecting the 
HIV-1 genome into fertilized mouse eggs (Reid et al., 2001). An interesting benefit of the AIDS 
rat is that the HIV-1 genome used as transgene does not include two important genes directly 
linked to the spread of HIV in humans, so the rats are much safer than previous monkey models 
infected with HIV, the risk of the disease spreading is minimized (Reid et al., 2001).  Rats allow 
bigger blood samples and organ extractions than mice, and also have certain proteins that 
facilitate HIV replication better than mice (Reid et al., 2001). With a nearly limitless supply of 
these rodent HIV models, researchers are now able to more effectively study how to identify 
early-onset symptoms of the disease, confirming proper diagnoses, and administering early 
treatment processes.  
 
Alzheimer’s Mouse  
 
Alzheimer’s disease (AD) is the most common form of dementia and affects 26.6 million 
people worldwide.  It is a progressive neurodegenerative disease that induces problems with 
language, decision-making ability, judgment, and personality (Kantor, 2010). This progression 
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has been linked to the abnormal formation of amyloid beta (Aβ) and its deposits in the brain 
(senile plaques), the fundamental cause of the disease.  Most animals do not get Alzheimer’s 
disease.  Occasionally, 60 year old orangutan monkeys develop it, but waiting 60 years to get 
your data is not a good model. 
The first AD disease model that developed a robust AD related phenotype was developed 
in 1995 in part here at WPI by Professor Adams in collaboration with Exemplar/Athena 
Neuroscience group (currently Elan Pharmaceuticals) (Games et al., 1995).  This mouse was the 
first of its kind to express a mutant version of the human amyloid precursor protein (APP) in the 
brain, which is associated with an early onset type of Alzheimer’s disease found in an Indiana 
pedigree.  This allows the mice to exhibit human-like Alzheimer’s symptoms in about 8 months 
(Games et al., 1995).  The model’s true worth can be seen in how AD research has progressed in 
recent years. Companies such as Elan Pharmaceuticals and Wyeth have used AD mouse models 
to develop Alzheimer’s vaccines. Although Elan Pharmaceutical’s initial vaccine showed 
adverse side effects, their subsequent second-generation vaccine appears to show no 
inflammation.  The benefit of an Alzheimer’s vaccine was discussed by Israeli researcher Dr. 
Alon Monsonego who stated: 
"Stimulating an immune response to Aβ in these humanized mice not only resulted in a 
highly efficient clearance of Aβ (plaque) from the brain, but also in a markedly reduced 
inflammatory reaction. The team was also able to predict that the characteristics of the 
immune response in mice were the same as in the human subjects” (Sheva, 2009).  
 
Interestingly, a recent article published in National Geographic News found that cell 
phone radiation has positive effects in reducing the development of Alzheimer’s in mice. The 
study found that if cell phone exposure began before the genetically engineered mice started 
showing symptoms, they were less likely to develop symptoms later in life (Than, 2010).  In the 
case of the AD mouse, fundamental research barriers such as the leap from the animal test 
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subject to humans were enabled due to the extensive testing allowed by the model. 
 
 
Oncomouse 
 
The oncomouse was the first transgenic animal to be patented.  This mouse was created at 
Harvard in 1984 by Philip Leder and Timothy Stewart (Stewart et al., 1984), and was genetically 
engineered to model many forms of human cancer by replacing the normal mouse myc oncogene 
with a myc fusion transgene under the control of a strong promoter to over-express the oncogene. 
As the mice and their offspring grew, they developed carcinomas, confirming that oncomouse 
was a successful transgenic model for cancer (Stewart, 1984). 
In 1988, U.S. patent 4,736,886 was granted to Harvard College for, “a transgenic non-
human mammal whose germ cells and somatic cells contain a recombinant activated oncogene 
sequence introduced into said mammal…” (Noonan, 2010).  This patent specifically excludes 
humans, which reflects the concern about patents on human life versus animal life, which will be 
discussed further in Chapters 3 and 4.  This mouse led the way to creating many other types of 
cancer mice, including those that develop cancer in specific organs.  Currently, the biomedical 
research field has at its disposal an ever-expanding set of mouse models of organ-specific cancer 
(Hanahan, 2007).  
 
 
Parkinson’s Fly 
 
Nearly 75% of known human disease genes have a recognizable match in the genome of 
fruit flies. The Drosophila genus, whose members are commonly referred to as fruit, pomace, 
vinegar, or wine flies, is currently being utilized to serve as a disease model for Parkinson’s 
disease, and other diseases. Parkinson’s disease is a neurodegenerative syndrome resulting from 
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the death of dopamine-generating cells in the substantia nigra, a region of the midbrain. 
Although the cause of Parkinson’s disease is unknown, mutations in the alpha-synuclein gene 
have been determined to be a major cause of Parkinson’s in genetic cases. The Parkinson’s fly 
model contains two point mutations of the alpha-synuclein gene (A30P and A53T), which are 
directly linked to the disease’s inheritance (Feany and Bender, 2000; Vogel, 2000). The fly’s 
nervous system formed normally, but after 30 days, the dopamine-generating neurons had 
deteriorated completely. Thus, the model mimics three important aspects of Parkinson’s disease: 
adult onset, nervous system involvement, and anatomical specificity (Feany and Bender, 2000).  
In recent studies, tests on the fly model have developed methods on how to effectively block 
dementia.  Dr. Paul Shaw stated:  
"Thanks to this model our labs have created, Dr. Galvin and I can not only quickly test 
potential new treatments for these symptoms of Parkinson's, we can also move up our 
treatments in terms of the timeline along which the disorder develops. That may give us a 
real chance to change the course of the disease." (Galvin and Shaw, 2009) 
 
 
 
TRANSPHARMERS 
 
Transpharmers are animals engineered to produce important proteins in the blood or 
milk.  Milk has become the most common site of production due to its ease of harvesting.  
Inserting a transgene into the animal under the control of a promoter for a milk protein ensures 
its production in milk. Prior to the development of transpharmers, proteins such as Human 
Growth Hormone (HGH) and insulin were usually harvested from human cadavers. 
Transpharmers drastically facilitate the production of these important proteins with no 
observable adverse effects on the animal itself.   
The first transpharmer models were mice engineered to express the clot dissolver drug 
tissue plasminogen activator (tPA) in milk (Gordon et al., 1987).  Rats were later used, and could 
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produce proteins such as human alpha-antitrypsin (hAAT) and human alpha-lactalbumin, which 
help treat emphysema (Fujiwara et al., 1997).  
As effective as transpharmer mice were, due to their size they did not yield nearly as 
much milk as companies desired, so farm animals such as goats, cows, and sheep were then used.  
The first successful transpharmer sheep were created in Edinburgh, Scotland by pronuclear 
injection of a fusion transgene containing a sheep milk protein promoter β-lactoglobulin (BLG) 
to drive the expression of the blood clotting protein factor IX (Clark et al., 1989).  The trait 
proved to be heritable.  Transpharmer goats were first produced in 1991 at the Tufts University 
School of Veterinary Medicine in Massachusetts to produce the clot dissolver drug tissue 
plasminogen activator (Ebert et al., 1991; Ebert et al., 1994). Like the sheep, the goats also 
passed the transgene to their offspring.  GenPharm International engineered the first transgenic 
cow, dubbed “Herman” in 1990, and his first transgenic offspring were bred at GenPharm’s lab 
in the Netherlands (Krimpenfort et al., 1991). Herman was modified to contain the gene for the 
multifunctional protein human lactoferrin, which is not found in either cow’s milk or synthetic 
milk. He fathered 8 calves, all containing the gene, and was eventually put down in 2004 for 
health problems unrelated to his genetics (Sterling, 2004). The transpharming field is arguably 
the most ethical form of transgenic practice, as no observable side effects are present in the 
subjects when compared to naturally born animals of the same species. 
 
 
XENOTRANSPLANTERS 
 
Organ transplantation is the procedure of moving an organ from one body to another for 
the purpose of replacing the recipient’s damaged organ. Until recently, human organ transplant 
operations could only be conducted if another human died with healthy organs intact, or a living 
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donor gave an organ that is not vital to their survival such as a kidney.  These are known as 
allotransplants, as they are performed between the same species.  Donated organs must also be 
histocompatible with the recipient or the body will reject the foreign tissue. For this reason, 
many of the 112,000 people in America awaiting organ donations will die without ever having an 
operation (OPTN, 2011).  
Xenotransplanters may be the solution to a very low supply of human organs. The most 
compatible animal has proven to be a pig due to its similar physiology and organ size compared 
to humans. The major obstacle for a compatible pig organ is due to the presence of a protein, 
alpha (1,3)-galactosyltransferase present in pig cells that catalyzes the production of galactose on 
the surface of pig cells. This causes the human body to reject the introduced tissue or organs. The 
most effective way to ensure compatibility with pig organs was discovered in 2002 at the 
Department of Animal Science at the University of Missouri where four pigs were created with 
the alpha(1,3)-galactosyl gene effectively knocked out (Lai et al., 2002).  The first “knockout 
pigs” showed successful eradication of the gene for one allele (mammals usually contain two 
copies of each gene), so the animal was heterozygous (Lai, 2002).  Later, in 2003, the pig line 
was bred to homozygosity (Sanchez, 2003).  But due to other immunologic problems that arise 
during human-pig xenotransplantation, further development is needed.  Dr. David Cooper of the 
Thomas E. Starzl Transplantation Institute of the University of Pittsburgh Medical Center 
remains hopeful, and states: 
"Advances in these areas might allow the initiation of clinical trials of xeno-
transplantation, at least for cell or islet transplantation or for the use of a pig organ to 
'bridge' a patient until a human organ is obtained. The potential benefits of successful 
xenotransplantation to large numbers of patients with very differing clinical conditions 
remain immense, fully warranting the current efforts being made to work towards its 
clinical introduction." (Xenotransplantation, 2007) 
 
 
 
30 
TRANSGENIC FOOD SOURCES 
 
The purpose of transgenic food sources is to provide animals that grow larger and mature 
faster on less food than their naturally born counterparts. This was accomplished by introducing 
growth hormones to the zygote for two types of food animals. 
 
Superpig 
 
The infamous Beltsville pigs, made in Beltsville, Maryland were created by genetically 
modifying them with an ovine metallothionein-1 alpha (oMT1a) promoter fused to ovine growth 
hormone genes. The MT promoter is constitutively always on, so the animals produce more 
growth hormone than usual.  As expected, they expressed higher levels of growth factors (Miller 
et al., 1989).  Unfortunately, despite growing radically faster and larger than naturally born pigs, 
the superpig developed many health problems after 6 months of age, including kidney and liver 
malfunction, ulcers, heart disease, and near immobilization due to extreme arthritis. For this 
reason, the pigs were euthanized, and further transgenic experimentation on mammals involving 
growth hormones ceased.  
 
Superfish 
 
Similar growth hormone modifications were performed on fish, and have been far more 
successful. Aqua Bounty Technologies, based in Massachusetts, has generated transgenic 
AquAdvantage salmon that grow to market size twice as fast as regular salmon while requiring 
less feed (Aquabounty Technologies, 2011).  These genetically modified Atlantic salmon have 
two foreign DNA sequences inserted into their genomes. One encodes a growth hormone from 
Chinook salmon, and the other is the on-switch promoter used by an antifreeze gene from ocean 
pout, an eel-like fish found in the Northwest Atlantic Ocean. When placed alongside the growth 
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hormone, this on-switch promoter makes the salmon produce the growth hormone in cold 
weather when they otherwise would not, so the salmon produce growth hormone year round 
rather than seasonally.  Importantly, the modified salmon do not grow larger than regular 
salmon; they just achieve their size in sixteen to eighteen months rather than three years.  The 
Food and Drug Administration (FDA) is considering whether to approve this salmon based on 
safety grounds alone (Gitig, 2010). 
 
 
SCIENTIFIC MODELS 
 
These transgenic animals are created with the intent to further understand genetic 
development and protein function through overexpressing certain genes or knocking them out.  
 
ANDi 
 
ANDi was the world’s first transgenic primate born on October 2, 2000.  To create 
ANDi, researchers injected 224 unfertilized rhesus eggs with a virus carrying the gene for green 
fluorescent protein (GFP) (Chan et al., 2001).  The virus's job is to integrate the gene into a 
random site on one of the chromosomes. Six hours later, each egg was artificially fertilized by 
sperm injection. Roughly half of the fertilized eggs grew and divided, reaching the four-cell 
stage.  Forty embryos were chosen and implanted into twenty surrogate mothers—two per 
mother. Of these, three healthy males were born and two twin males were stillborn. ANDi was 
the only live monkey carrying the GFP gene (Trivedi, 2001).  GFP direct fluorescence was 
detected in his toenails and hair, however ANDi does not glow (Chan et al., 2001).  It has been 
recently proven that primates can pass the transgene to their offspring.  Scientists of the Central 
Institute for Experimental Animals in Kawasaki, Japan, gave marmosets the GFP that made them 
glow green under UV light. When the single male of four transgenic newborns was sexually 
 
32 
mature, he successfully fathered a single offspring, which also glowed green, showing the trait 
was heritable (Coghlan, 2009). ANDi has proven that primates are able to accept foreign genes 
and has possibly opened the door to future human transgenic procedures. 
 
Smart Mouse 
 
The Smart mouse, dubbed “Doogie”, was created at Princeton University in 1999 (Tang 
et al., 1999).  Doogie is a strain of mice that is genetically modified to have improved learning 
and memory. In a novel object recognition test, the mice were given the chance to become 
familiar with two objects.  Later, when one object was switched for another new object, Doogie 
mice quickly recognized the switch and devoted time to exploring the new object instead of the 
old one. Normal mice spent equal time exploring the new object and the old one (Tsien, 2000). 
The improved cognitive ability is accredited to the overexpression of NR2B receptors in synaptic 
pathways.  This change means that the mice have juvenile-like brain features with regards to 
memory retention, which are believed to be more efficient at retaining large amounts of new 
information. 
 
Supermouse 
 
Supermouse was created using the same parameters and principles as the previously 
mentioned Superpig and Superfish, and represents the world’s first expressing transgenic animal 
(Palmiter et al., 1982).  By microinjecting mouse newly fertilized eggs with rat growth hormone 
genes, the newborn transgenic mice grew faster and much larger than their naturally born 
littermates. The Supermouse was the first transgenic animal ever created with observable 
changes in its physical traits and development, and paved the way for producing other transgenic 
animals. The success of Supermouse also showed potential as a means to take preventative 
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measures against dwarfism, gigantism, and other genetic diseases affecting height (Palmiter et 
al., 1982). 
 
Youth Mouse 
 
Youth mouse was created at the Department of Biochemistry, Weizmann Institute of 
Science, Rehovot, Israel in 1997.  The mice overexpress the urokinase-type plasminogen 
activator, which acts as a clot dissolver. The mice are smaller, eat less, and live nearly twenty 
percent longer than normal mice of their type (Miskin and Masos, 1997). It is believed that the 
overexpression of the plasminogen activator extends the lifetime of the mice by preventing 
atherosclerosis, a process that develops plaques in the arteries of an animal as it ages. Recent 
experiments have also succeeded in reversing the effects of age, using telomerase, an enzyme 
that synthesizes small segments of DNA that seal the tips of chromosomes, which prevent genes 
from deteriorating.  When scientists increased the levels of telomerase in mice, their organs 
began to rejuvenate (Hastings, 2010).   
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CHAPTER-3: TRANSGENIC ETHICS 
Paul Cupido 
 
 The human-animal relationship has existed for millions of years and continues to evolve 
to this day.  Without the use of animals and science, our species would have struggled to survive, 
as throughout history animals have provided us with means of food, transportation, fertilizer, 
clothing, and protection.  It was during the time of the Roman physician Galen (AD 129 – c. 
216) that using animals for obtaining knowledge about human biological processes first became 
popular.  By dissecting apes, sheep, pigs, and goats, Galen developed skeletal anatomy and an 
understanding of nerves, along with more epochal disciplines of medicine (Porter, 2003).  Since 
then, the human-animal relationship has evolved to the pinnacle of biotechnology, as transgenic 
animals and genetic modifications now help to further our knowledge pertaining to our species.  
Despite all the advancements being made with this technology, the use of transgenic animals has 
received a lot of scrutiny regarding ethical beliefs.  Many argue against using animals for testing 
due to reasons of cruelty, morality, and religion.  Ethical concerns regarding jeopardizing the 
safety of our environment also creates arguments, as genetic engineering is viewed by many as 
an act of “playing god”.  This practice is nothing new, as selective breeding to create more useful 
varieties of plants and animals has been a form of biotechnology that human beings used even 
before Galen’s time. 
 Since the dawn of man’s existence on Earth, we have been selectively breeding animals 
and plants to better serve us for work and domestication purposes.  On the large timescale of 
human history, our race has just recently been granted the power of changing an organism’s 
genetic code at will.  Ethics and science have always gone hand in hand. Now more than ever, 
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ethics should be considered, as genetic engineering continues to become known as “the most 
powerful technological tool ever possessed by humanity” (Rollin, 1996).  Still, the importance of 
ethics within the scientific community often goes unseen, therefore hindering the advancement 
and development of controversial technologies.  Genetic engineering especially has distanced 
itself from the public, as most people are misinformed and define the issues dealing with 
transgenesis erroneously (Rollin, 1996).   
 As with any argument pertaining to ethics, it is important to understand conflicting 
opinions in order to be most informed when making a conclusion.  With transgenic animals some 
people believe that animals have their own rights, and using them for human benefit is unjust.  
Others hold the need of humans above that of animals, and turn a blind eye to all animal 
experimentation.  There is no right or wrong answer to any ethical question, but a compromise in 
between these two opposing views appears to hold a rational solution.  Forming an extreme 
opinion on transgenic research seems to be based on a lack of knowledge on the subject.   
In terms of injustice, it is not fair to form a blanket policy on such an important piece of 
biotechnology.  A key matter often overlooked is that each category of transgenic animals differs 
from one another.  Disease models, transpharmers, xenotransplanters, food sources, and 
scientific models, each induce independent ethical discussions.  If transgenesis is first examined 
as a whole and then broken down into its individual categories, the ethical balancing act that 
takes place between the benefit to society and the detriment to the animal will become more 
apparent.  
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The Costs and Benefits of Transgenic Animals to Society 
  Opponents of transgenesis claim that animal experimentation is detrimental to society, to 
the environment, and to the animal.  Despite the importance of transgenic animals to science 
(discussed in Chapter-2), common misconceptions raise concerns about the use of animals in the 
laboratory.  The first belief critics hold is that transgenic animals suffer more when compared to 
a regular research animal.  It is believed that the introduction of foreign DNA often causes 
unpredictable and painful mutations not intended by the researcher in an experiment.  While the 
process of successfully transferring foreign DNA into a living animal is unpredictable, inefficient 
and complex, mutations often impact highly specific metabolic processes or cell receptors 
without actually causing disease, discomfort, pain or malformation in the animals 
(GlaxoSmithKline, 2007).  The opponents of transgenic research are correct in that the process of 
successfully expressing a gene in a living animal does not have a high success rate.  Thus, a high 
percentage of the animals that do not express the foreign DNA are eventually destroyed, as they 
are no different than wild type mice used at the beginning of the experiment.  This matter is most 
alarming to organizations such as PETA (People for the Ethical Treatment of Animals) and the 
ASPCA (American Society for the Prevention of Cruelty to Animals), who relentlessly campaign 
to stop procedures such as transgenesis with statements like the following:  
 
“More than 100 million animals every year suffer and die in cruel chemical, drug, 
food and cosmetic tests, biology lessons, medical training exercises, and 
curiosity-driven medical experiments” (PETA, 2011). 
 
There are some forms of transgenic research that do cause pain or even death to the animal 
subjects, for example the Oncomouse and Superpig.  The Oncomouse was created by inserting 
an oncogene that increased its susceptibility to cancer, while the Superpig was given HGH 
(human growth hormone).  Superpig suffered immensely before inevitable euthanasia.  However, 
not all disease model animals exhibit this misfortune contrary to popular belief and will be 
discussed later on. 
 
40 
   Some skeptics believe that transgenesis comes at the cost of violating religious beliefs.  
Four major religions: Hinduism, Judaism, Islam, and Christianity surprisingly seem to leave 
animal rights open for individual interpretation.  Hindus believe that non-human animals are 
inferior to human beings, but the cow is considered to be sacred (British Broadcasting 
Corporation, 2010).  To Hindus, to kill or harm a cow is a horrible crime as Hinduism teaches 
that cows have feelings similar to humans.  Judaism places great stress on proper treatment of all 
animals, as they are accorded the same sensitivity as a human (Rich, 2011).  However, there is 
no definitive opinion in Judaism as to whether animals experience psychological and physical 
pain in the same way humans do.  The Qur’an shares similar beliefs that animals have feelings.  
Islam does in fact support testing on animals as long as the goals of improving human health or 
human safety are respected. Christianity on the other hand does not have clearly defined beliefs 
when it comes to animal rights and using animals to benefit mankind.  
  Members of activist groups such as PETA believe all animals deserve moral 
consideration.  Such a view creates problems when society is trying to resolve cases where the 
moral interests of different animals are in conflict.  An interesting and reasonable way to 
distinguish which animals are suitable for experimentation is to arrange the organisms in a moral 
hierarchy.  This approach is what philosophers call consequentialism (Singer, 2011).  Organisms 
are arranged in three tiers, each containing organisms that deserve different amounts of moral 
consideration.  The lowest tier consists of inanimate objects and simple organisms which deserve 
no moral consideration.  Examples in this tier are insects and plants.  The second tier is 
comprised of sentient organisms that are not self-aware and don’t have any idea of continuing to 
exist in nature (Singer, 2011).  Fish and rodents are occupants of this tier.  These are animals that 
can feel pain and pleasure, but prefer to avoid pain.  It is still considered wrong, under this 
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ideology, to cause pain to the members of this group.  Killing and replacing individuals in this 
tier however is not significant because one individual is not significantly different from another 
(Singer, 2011).   The third grouping includes humans and more complex and cognitive animals.  
These species are fully aware.  This tier attracts the most moral value for animals.  This ranking 
of hierarchy helps to justify using transgenesis on the second and third tiers of animals in a 
humane way.  
  Another potential negative aspect of transgenesis is that it poses a huge threat to 
humanity, even with as many problems it can solve within our species.  Tinkering with nature 
and the natural order of evolution could drastically disrupt biodiversity.  If a transgenic animal 
bred to be stronger, faster, and healthier ever escaped and mated with the wild population, the 
effects it would have on the species could do unimaginable damage.  “Playing God” has its 
consequences, but is it necessarily wrong?  The argument against this thought is that the human 
race has evolved to where it is today by altering the environment and nature.  It is hard to 
understand why damming rivers, eradicating smallpox, and building cities and civilizations, is 
not also intrinsically wrong in this sense (Rollin, 1996). 
    Overall, it is appropriate to recognize the benefits of transgenic research as being 
monumental for science.  The contributions to human welfare created through transgenic 
research can be grouped into three categories: Agriculture, Medicine, and Industry.  Transgenic 
animals have helped farmers by providing them with animals equipped with better milk 
production and higher growth rates (Margawati, 2003).  Transgenic cattle and pigs now exist 
with more meat on their bodies along with sheep that produce more wool.  The quality of 
animals used for agriculture has significantly increased as genetic engineering can now provide 
disease resistant animals such as influenza-resistant pigs.  In medicine, animals modified for 
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xenotransplantation provide new hope for patients on organ-donation waiting lists.  Products 
such as insulin, growth hormone, and blood anti-clotting factors used as supplements and 
pharmaceuticals can be obtained through the milk of transpharmer animals.  Herman the 
transgenic bull was produced in 1991, and is known as the first genetically modified bovine in 
the world.  At the embryo stage Herman was microinjected with human gene coding cells for 
lactoferrin, a key protein in the human immune system. He was allowed to reproduce and 
fathered 55 calves, all containing the lactoferrin gene.  Transgenic cows like Herman, have been 
used widely to produce hormones and human protein-enriched milk for treating those with 
digestive and other needs.  It is hard to even fathom the potential transgenesis has when it comes 
to curing and treating genetic disease.  The world’s first spider-goats, Webster and Pete 
(Highfield, 2002), produced spider silk in their milk for industrial applications.  They inspired a 
breed of offspring which can produce spider silk for use in military uniforms, medical 
microsutures, and tennis racket strings (Margawati, 2003).  Today, the Netherlands Forensic 
Institute has combined its work with Randy Lewis, the creator of the spider-goat to make 
bulletproof skin (Fattah, 2011).   
 Transgenic animals can be divided into individual categories and further examined to 
provide full insight on ethical issues dealing with this subject.  When analyzing the costs and 
benefits of this technology as a whole, the differences between each group of animals are often 
not realized.  Disease model animals are the most controversial as they appear to the public as 
the class that exhibits the most pain and suffering.  While they raise questions pertaining to 
animal welfare, transpharmer animals on the other hand almost seem to escape all ethical 
scrutiny.   
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Disease Model Ethics 
 Transgenic animals created to be disease models incorporate genes which will cause the 
animal to exhibit some symptoms of human disease.  This allows scientists to learn more about 
significant disease and test potential treatments before exposing a human to the dangers of 
preliminary testing.  Disease model animals save money, time, and most importantly lives.  
Giving an animal a partial human disease seems cruel, and can put an animal through a great deal 
of suffering.  Disease model animals perhaps are victims of the harshest ethical judgment.  Not 
all disease model animals suffer though.  For example the Alzheimer mouse experiences no pain, 
yet it grants scientists the hope to cure the 6
th
 leading cause of death in the United States 
(Alzheimer’s Association, 2011).   Developed at WPI by Professor Adams and the former 
Transgenic Sciences Inc., the Alzheimer disease model mouse expresses the human mutant β-
amyloid precursor protein (APP) linked to autosomal dominant forms of Alzheimer’s disease.  
This mouse is the first successful animal model to be transgenic for APP, and shows signs of 
neuro-degeneration.  The only suffering this animal exhibits is a slower cognitive speed.  This 
disease model led to the development of the first testable vaccine for Alzheimer’s disease made 
by Elan Pharmaceuticals (Schenk et al., 1999). 
 The Oncomouse however, clearly can endure pain as a transgenic animal, especially if 
the tumors are grown to the advanced stage.  Genetically modified to develop cancer, the mouse 
is extremely susceptible to tumor growth.  This is done by introducing an oncogene specific to 
triggering the development of tumors into the mouse’s genetic code (WIPO, 2006).  This 
controversial animal generated many ethical issues as the creators sought patents in numerous 
countries.  They succeeded in obtaining a patent in the United States, Europe, and Japan.  But the 
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Canadian Supreme court denied the patent in 2002, claiming that the only major issue with the 
Oncomouse was that life should not be patented. 
 
Xenotransplanter Ethics 
 The xenotransplanter branch of transgenic animals is an interesting topic for ethical 
discussion.  The need for organs rises annually, and genetically modified animals can help 
resolve this problem.  There are approximately 111,000 individuals currently in the U.S. 
awaiting organ transplants (Organ Donor, 2011), while only about 14,000 individuals donated 
organs in 2010 (Donate Life America, 2011).  Transgenic animals can be tailored and 
customized to grow vital organs and save thousands of lives.  Implanting organs into humans 
from animals does have its risks.  The organ can be rejected by a patient’s immune system and 
animal viruses can be spread to humans.  The cross species infection of a virus can create a very 
dangerous situation.  This can create a new human strain of a virus which would require time to 
create vaccines and treatments for.  However, pre-transplant pathogen screening can prevent the 
potential outbreak of a new strain of virus.   
 
Food Source Ethics 
 An animal whose genetic code has been altered to increase the rate at which it grows is 
considered a transgenic food source animal.  The ‘Beltsville pig’, was one of the most 
controversial transgenic food source animals, as it was obvious how much pain it endured.  The 
Beltsville pig, also known as the Super pig, was given a gene for a human growth hormone with 
the goal of creating larger animals with leaner meat.  The pig reached enormous size, but it 
became deformed as it could not support its own weight, and it also suffered from severe arthritis 
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and various organ failures.  Many people view this transgenic case as a complete failure.  It is not 
normally recognized that this animal actually led to the development of the Superfish.  Altered in 
a similar manor, Superfish have an immaculate growth rate, gain size quickly, suffer no apparent 
illnesses, and require less feed.  Superfish are considered to be safe by the FDA, but congress 
shot down the first genetically altered animal ready to be marketed for consumption in the U.S. 
(Rain, 2011).  Food source animals are very important to the progression of humanity as they can 
help combat seemingly impossible problems to solve, such as world hunger.  Food source 
animals can be brought to slaughterhouses quicker because they require less time to grow.  This 
can help drive down the price of certain foods as companies can increase the amount of animals 
processed for consumption daily.  As long as animals in this transgenic category do not suffer 
from the presence of the transgene (like Superfish), there appears to be no other ethical concern 
besides sacrificing the animal for food, which already occurs daily in order for our species to 
survive. 
 
Transpharmer Ethics 
 Transpharmer animals are engineered to produce large amounts of a particular hormone 
or protein in their blood or milk.  This category of transgenic animals receives not nearly as 
much ethical debate as the other animal groups.  No direct harm or pain has been proved to be 
inflicted on these animals.  Transpharmers provide a high yield of product at a low cost.    The 
morality of transpharmers should not be questioned as they possibly could increase the 
availability of drugs for people who can’t receive such treatments.    
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Chapter-3 Conclusions 
 After examining each main division of transgenic animals it is clear that transgenic 
research needs to continue pushing forward.  The negative side effects seem harsh in some cases, 
but the possibility of creating a new viral disease or disrupting biodiversity by breeding with 
wild type animals can be prevented by taking the proper precautions.  When considering using 
animals for medical purposes, it is necessary to consider whether the pain and suffering of the 
animals is justified by the potential benefit to human beings (Nuffield Council on Bioethics, 
2011).  The potential transgenic technology provides human beings is enormous, and can justify 
experimentation in its own.  When pertaining to animal welfare, inhumane treatment of animals 
cannot be overlooked, and institutional Animal Care and Use Committees (IACUC) should 
continue to provide strong oversights to prevent needless suffering.  Animals should be 
considered to share common rights with humans, but shutting down animal research because of 
this belief would be detrimental to society.  Humanity has been granted a gift from hundreds of 
years of hard work and study.  It would be a shame to waste such technology, that when used 
correctly could solve the world’s most challenging problems.        
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Chapter-4:  Transgenic Legalities 
 
Philip O’Sullivan 
 
 
Controversial technologies, including transgenics, are regulated by society through laws. 
Subjects such as whether animals should be patented are highly controversial, and often blend 
ethics with legal issues, especially regarding determining whether legal precedents have been 
established, or determining whether transgenic animals should be sold for profits.  The legal 
cases that decide whether animal life can be owned are complex, and do not always turn out the 
same way in various countries.  This chapter will discuss transgenic legalities, and investigate 
where lines should be drawn. 
 
PATENT ISSUES 
In general, patents serve to protect intellectual property, providing benefits to the 
invention creator, and blocking competition for a period of time.  Title 35 of United States Code 
101 states that: “Whoever invents or discovers any new and useful process, machine, 
manufacture, or composition of matter, or any new and useful improvement thereof, may obtain 
a patent therefor, subject to the conditions and requirements of this title” (Bitlaw, 2000).  So 
patent law requires the invention to be new, and to be a process, machine, manufacture, or 
composition of matter.  So the question becomes where do animals fit in this language.  The U.S. 
Patent and Trade Office (PTO) also requires that a patent submission must satisfy the three 
requirements of novelty, utility, and non-obviousness. All guidelines considered, there is no 
evident regulation that distinguishes that patentable property can be either living or non-living. 
In addition to the PTO controlling patenting, the government’s Federal Drug 
Administration (FDA) is also a major player in the control of transgenic products.  The FDA 
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decides how genetically engineered animals will be evaluated to benefit the public, and decides 
whether their products, such as transpharmed drugs or Aqua Bounty’s superfish are suitable for 
consumption. Such animals will be regulated under the Federal Food, Drug, and Cosmetic Act; 
the recombinant DNA in the animal is sometimes considered the “drug”, and its safety and 
environmental impact are investigated by the FDA (FDA to Regulate the Use of Transgenic 
Animals, 2009).  Strong FDA involvement is evident in the recent developments regarding the 
market release and distribution of Aqua Bounty’s genetically enhanced superfish (Marris, 2010). 
 
PATENTING LIFE,  DIAMOND V. CHAKRABARTY 
 The first case of patenting any living organism occurred in 1980. Genetic engineer 
Ananda Chakrabarty had developed a bacterium capable of breaking down crude oil, and 
proposed it would be a major benefactor to the rapid treatment of oil spills. The presiding patent 
examiner initially turned down his request, as at that time no legal precedent existed for 
patenting life.  However, Chakrabarty persisted, and eventually the United States Court of 
Customs and Patent Appeals later overturned the original negative decision in Chakrabarty’s 
favor dictating that, “the fact that mico-organisms are alive is without legal significance for 
purposes of the patent law” (Diamond v. Chakrabarty, 1980). This case served as a landmark for 
later patents for genetically modified animals and stem cells. 
 
THE ONCOMOUSE COURTCASE 
ONCOMOUSE IN THE UNITED STATES 
Harvard and DuPont’s Oncomouse was the world’s first patented animal.  Originally 
filed in 1984 (Leder and Stewart, 1984) it finally received patent number 4,736,866 on April 12, 
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1988, and continues to be the center of the animal patent universe.  The original patent covered 
all mammals containing oncogenes, and specifically included the original animal that first 
received the oncogene and the process used to create it (Leder and Stewart, 1984). DuPont’s 
licensing fee was originally high, and many researchers were concerned that DuPont’s licensing 
could slow the testing of new cancer therapies, as only the rich labs could afford to pay the 
licensing fees (Smaglik, 2000).  To overcome this problem, DuPont and the US National 
Institutes of Health (NIH) negotiated a deal giving non-profit researchers free access to the 
mouse with the stipulation that any commercial users must pay for the mice (Smaglik, 2000). 
Still, researchers argue that the use of licensing fees will deter research by causing an economic 
burden.  The Oncomouse patent also drew controversy from many animal rights organizations, 
arguing that animals should not be patented.  To date, the authority to grant a patent on life has 
been subject of many court cases. 
 
ONCOMOUSE IN EUROPE 
The success of the Oncomouse patent in the US was followed by DuPont’s patent filing 
in Europe.  DuPont’s 1989 European proposal was initially refused, but the case was later 
appealed and granted on the grounds that while Article 53(b) of the European Patent Convention 
1973 (EPC) states that animals are excluded from patentability, Article 52(1) states that patents 
are available for all inventions capable of industrial application, and therefore under this article, a 
transgenic animal could be seen as capable of industrial applications (European Patent 
Convention, 1973).  Following this case, a debate led to the adoption on 6 July 1998 of EU 
Directive 98/44/EC on the legal protection of biotechnological inventions, known as the "Biotech 
Patent Directive" whose purpose is to clarify the distinction between what is patentable and what 
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is not.  For instance, an invention relating to individual human, animal, or plant genes and gene 
sequences, and their functions, can be patented in Europe as long as the other patentability 
criteria are also fulfilled.  However, the directive rules out the patenting of an entire human body, 
and eliminates applications for procedures designed to allow human cloning, human germ line 
engineering, or the use of embryos for industrial or commercial purposes (EPO – Biotechnology, 
2011).  The European Oncomouse case was officially resolved in June of 2004 in favor of 
DuPont.  Today, European court cases continue to debate the future of patents for stem cells and 
human genes. 
 
ONCOMOUSE IN CANADA 
In Canada, the patent examiner initially rejected claims to transgenic animals on the basis 
that they were not included in the patent definition of an invention. Once again, DuPont appealed 
this decision.  But in this case, the Supreme Court of Canada finally ruled in 2002, through a 
close 5 to 4 vote, that higher life forms were not patentable because they are not a "manufacture 
or composition of matter within the meaning of invention" of the Canadian Patent Act (Harvard 
College v. Canada, 2008).  Manufacture was interpreted as a non-living mechanistic product or 
process, while "composition of matter" was understood to be ingredients or substances that had 
been combined or mixed together by a person. So while microorganisms, or in this case, an 
oncogene-injected egg capable of maturing into an Oncomouse, may be a mixture of ingredients 
and thus in theory patentable under Canadian Law, the body of a mouse, which was not 
combined or mixed together by a person, was not (Bioethics and Patent Law, 2006). The denial 
of Oncomouse in Canada has been a rallying point for activists who argue that animal patenting 
can create barriers preventing the free and rapid dissemination of scientific research materials 
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which, in turn, affects the discovery of drugs and treatments (Check, 2002). 
 
BENEFITS OF ANIMAL PATENTABILITY 
When determining whether a specific patent is fair or ethical, it is important to 
understand the basis behind the patent itself.  When applying for a patent on a transgenic animal, 
the individual or company is attempting to secure protection for their idea. In the case of 
Oncomouse, Harvard and DuPont devoted time and money to the research and development of a 
transgenic animal that serves as a model for screening anti-cancer drugs and aiding our 
understanding of oncogenesis.  Their attempts to patent their creation strive to secure financial 
benefits for their pioneering work, and to ensure proper recognition as the original developers of 
this idea.  Competition has always been a main driving force in the business world.  Michael E. 
Porter proposes that the threat of new entrants, the power of buyers, the power of suppliers, the 
threat of substitute products and services, and the threat of current competitors are “the five 
forces that shape industry competition” (Porter, 2008).  
DuPont, above all, is a business striving to ensure financial gain and product success. 
Without proper protection of their ideas, other companies or research teams could easily replicate 
the necessary processes to derive their own benefits from DuPont’s research, effectively leveling 
the competition barriers between companies and severely constricting the returns from DuPont’s 
original investment.  Proponents of business competition would argue that patenting drives the 
business world, edging businesses to strive for more cost-effective, durable, quality products.  
A further stimulus for allowing the patenting of animals is that financial return has the 
potential to be reinvested and thus promote further research and development, boosting medical 
research. Without patent protection, these economic incentives would be non-existent, and the 
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biotechnology market would suffer.  If patented animals prove to be profitable, more companies 
will fund this type of medical research.  So as to the benefits of patenting transgenic animals, 
patent protection essentially motivates companies to create great new technologies and ensures 
their security as they are entitled to the rewards of their investments.  
 
HINDRANCES OF ANIMAL PATENTABILITY 
On the negative side to allowing animal patenting, entitling an idea to only one 
benefactor can make it difficult for others to utilize the product.  In the Oncomouse case, the 
scientists at Harvard required that anyone looking to use the mouse must obtain a license to do so 
(Marshall, 2002).  Thus, if researchers wish to use mice as cancer disease models, they have to 
either create a variation in DuPont’s process to create a new model, or buy directly from DuPont. 
Financial strain can hinder research, especially if the animal is not readily available for shipment 
or if experiments are time-sensitive.  
 Attaining patents on animals could also act as a gateway for allowing human patents.  
The idea of patenting human life may initially seem ludicrous, however allowing patents on 
human cell lines could help create universal donor stem cell lines, or transplantable tissues and 
organs.  Despite laws restricting the patenting of humans, a portion of a human, the human 
oncogene was placed inside Oncomouse, and the patent was allowed. Organs reside inside 
humans, and genetic engineering could be performed on them.  Loopholes such as these could 
easily be exploited as patent grants become more available for establishing precedence. 
 Much resistance of the transgenic animal research field comes from animal rights groups 
such as People for the Ethical Treatment of Animals (PETA) and the Anti-Animal Vivisection 
Society (AAVS).  These groups are morally opposed to the idea that any animal be created to be 
 
55 
used in research. More importantly, animals born with defects that cause them pain, such as the 
Superpig, or hinder their functionality such as the “Dry-Eyes” rabbit (born with hindered 
eyesight so that it can serve as a model for the dry-eye human condition), have to endure a 
miserable existence before being ultimately killed (Stopanimalpatents.org, 2011).  The idea of 
animals being created merely for their own suffering is why many people advocate for the 
protection of animals so that none are created under such circumstances. This point is the driving 
force balancing the ethics of the needs of humanity versus the needs of the individual animal. 
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Project Conclusions 
 
 In order to deepen our understanding of the controversial topic of transgenic animals, and 
form an opinion on whether to support it, it is first important to understand what exactly a 
transgenic animal is and how they are made.  A transgenic animal is an organism containing 
foreign DNA inserted in its genome.  It does not have to express the inserted DNA to be 
considered a transgenic animal, but the transgene must be expressed to give the animal a new 
phenotype or characteristic.  Transgenic animals can and have already offered great advantages 
to the agricultural, industrial, and medical fields of science.  However, this topic as a whole is 
considered very controversial as animal experimentation is viewed by some to be detrimental to 
the animal.  Therefore, a thorough discussion of this topic must include transgenic ethics and 
legalities. 
There are numerous methods for creating a transgenic animal.  The two most widely used 
methods are pronuclear microinjection and embryonic stem cell manipulation.  Each method first 
requires the creation of a transgene, or the piece of foreign DNA that will be inserted into the 
animal.  A transgene consists of three main structural components, the promoter, the protein 
coding sequence, and a stop codon.  The promoter helps signal in which tissue the foreign gene 
will be made in the animal, while the protein coding sequence dictates the new properties given 
to the animal.  In the case of pronuclear injection, many copies of the transgene are directly 
injected into preferably the male pronucleus of a fertilized egg.  Although pronuclear 
microinjection is a relatively reliable method of transgenesis, the desired gene integrates within 
the host DNA randomly.  The integration site is critical in determining the transgene’s 
expression, so its function can be impaired if the transgene integrates in an inactive area of the 
 
58 
chromosome, even though the transgene is present in the genome.  Thus, pronuclear 
microinjection does not present the most efficient method of transgenesis.  Embryonic stem cell 
manipulation involves inserting the transgene into the stem cells of a blastocyst.  The transgene 
can be inserted via a virus, by microinjection, homologous recombination, or with the use of 
specific chemicals.  Using some viruses (AAV-5) or homologous recombination allow 
integration site control, and the ES cells can be screened for positives before injecting them back 
into the blastocyst making this method more efficient.   Both transgenic methods use a 
polymerase chain reaction (PCR), or a Southern blot analysis to screen the newly born offspring 
for successful integration of the desired gene.  The advantage with embryonic stem cell 
manipulation is that the screening for the presence of the transgene can be performed to the 
cultured cells before re-implantation. This method is time consuming but has a greater 
efficiency.   
Transgenic animals are divided into five categories:  disease models, xeno-transplanters, 
transpharmers, food sources, and scientific models.  Disease model animals are engineered to 
express the symptoms of a particular disease or illness for further scientific study.  The 
Alzheimer’s mouse for example, grants scientists the privilege of having an inexpensive and 
easily maintainable test subject for suspected treatments.  Having this animal model available 
can help reduce the required time and cost of research for treatments.  Xenotransplanters are used 
to grow valuable organs compatible for human transplantation for helping with the organ 
shortage.  Transpharmers express a human drug in their milk, for example insulin or clot 
dissolver proteins.  Food source animals are altered to grow bigger and more quickly to increase 
the efficiency of food production, to help drive down the price of food.  Superfish are perhaps 
the most promising food source animal created to date.   
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 The topic of transgenic animals receives a lot of criticism regarding the ethics behind the 
technology.  Animal rights protection organizations such as PETA are constant opponents of 
animal experimentation.  Although this organization states some valid arguments pertaining to 
the overall low efficiency of transgenesis, they often overlook the fact that not all transgenic 
animals endure a life of cruelty.  When analyzed by individual categories, transgenic animals are 
not as unethical as opponents would like one to believe.  Some disease model animals suffer the 
most pain, while the other divisions of transgenic animals do not appear to suffer at all.  
It is concluded that the benefits to society that transgenic technology provides human 
beings justifies this experimentation on its own.  When considering animal welfare, inhumane 
treatment of animals cannot be overlooked, and institutional Animal Care and Use Committees 
(IACUC) should continue to provide strong oversights to prevent cases of needless animal 
suffering.  Instead of considering all transgenic animals to be unjustified, each type of altered 
animal should be considered separately.  It is encouraging to see laws continually forming to 
provide strong oversight of this technology, creating situations in the laboratory which minimize 
animal detriment as much as possible. 
 
